China is no longer just a low-cost manufacturing hub—it has become a global engine of healthcare innovation. Across drug discovery, development, and commercialization, the country’s scale, speed, and integration into global pharmaceutical value chains have reshaped its role. To understand what’s coming, we believe investors should focus less on individual breakthroughs and more on the structural advantages driving China’s next phase of growth.
Four Growth Drivers
China’s advantages in healthcare and drug development reflect a combination of scale, cost efficiency, process strength, and entrepreneurial intensity. Together, these factors support a development model that is faster, more iterative, and tightly integrated with global pharmaceutical value chains.
Large, underpenetrated patient base. China’s sizable and still underpenetrated patient population enables rapid clinical enrollment and generates large datasets across diverse indications. This supports faster proof-of-concept timelines and increases the global applicability of trial results.
Lower-cost, faster development. Clinical trials and drug development in China are meaningfully less expensive and quicker to execute than in most developed markets. Shorter timelines allow companies to iterate rapidly, refine dosing and trial design, and move assets through development more efficiently.
Process engineering and manufacturing scale. China’s strength in process engineering and large-scale manufacturing provides a structural advantage once therapies reach commercialization. The ability to scale production quickly supports cost leadership, accelerates learning curves, and enables companies to capture global market share in manufacturing-intensive modalities.
Entrepreneurial intensity and rapid iteration. A highly competitive, entrepreneur-driven ecosystem emphasizes speed, experimentation, and optionality. Historically, more permissive regulatory frameworks have allowed companies to test aggressively and iterate quickly. While this approach carries risk, it has also driven continuous improvement in development efficiency and execution.
Set against these advantages, we believe the primary structural constraint in Chinese healthcare has been weak domestic pricing and reimbursement economics. As a result, many companies have adopted a “develop locally, monetize globally” model—using China’s patient base, clinical infrastructure, and manufacturing capacity to develop therapies that are then licensed or commercialized in international markets. This model is becoming a defining feature of China’s role in the global healthcare ecosystem.
Two Structural Growth Drivers
Two major forces are driving growth in Chinese healthcare.
First, we are seeing a sustained increase in innovative drugs reaching the market. Drug development is becoming less of a pure discovery exercise and more of an engineering challenge, combining validated mechanisms, targets, and delivery systems in novel ways. China has developed a clear advantage in this model. The ability to iterate quickly, run trials efficiently, and refine dosing or combinations has improved both development speed and probability of success, leading to a steady rise in globally competitive assets.
Second, China dominates the process layer of healthcare. North Asia has long led in process technologies—such as semiconductors and contract manufacturing—and healthcare is no exception. Chinese CDMOs are among the most cost-effective, fastest, and most scalable globally, allowing them to steadily capture market share. Over the past decade, clinical trial activity in China has expanded dramatically, and in several drug categories China already accounts for more than 50% of global trial volume, particularly in areas where innovation is based on recombining validated approaches.
Expansion Beyond Oncology
China’s biotech industry initially focused on oncology—the largest and most globally monetizable therapeutic area—and has since been expanding into additional modalities such as immunology and metabolic diseases.
Licensing activity has accelerated meaningfully. China’s advantage has not been demand-driven, but execution-driven—characterized by a greater willingness to take an aggressive approach to clinical trials and iterate quickly, enabling companies to reach viable solutions faster.
As a result, we have seen a rising number of multibillion-dollar licensing deals involving tier-one Chinese biotechs and pharmaceutical companies. This has created a self-reinforcing cycle: capital inflows support faster development, which in turn drives additional out-licensing and partnerships.
The next phase of China’s biotech development is global expansion. Leading Chinese healthcare companies are beginning to build their own international infrastructure. One has already established a meaningful international presence, but it remains an exception rather than the norm today. However, over the next five to seven years we expect the emergence of multiple globally competitive pharmaceutical companies from China.
China’s Central Role in Global Supply Chains
From a manufacturing perspective, global healthcare supply chains are deeply dependent on China. In areas such as peptides and GLP-1 therapies, Chinese CDMOs remain critical, with alternative manufacturing efforts in other regions proving difficult to scale at comparable quality and cost.
High-Conviction Subtheme: Bioconjugation
One of the most compelling subthemes within Chinese healthcare is bioconjugation. Here, innovation is driven by combining two proven components—such as peptides and monoclonal antibodies—to improve patient outcomes.
The enabling force behind bioconjugation is process excellence, particularly in CDMOs. We believe companies such as WuXi XDC and WuXi Bio are well positioned in areas such as bioconjugates and bispecifics, where scale, precision, and manufacturing expertise are decisive advantages.
Where else do we see growth in China? In part one of this series, Vivian Lin Thurtson discussed AI; in part three, Pierre Horvilleur discussed biotech and advanced manufacturing.
Andrey Glukhov, CFA, is a research analyst on William Blair's global equity team.
Justin Lin, CFA, is a research analyst on William Blair's global equity team.
China Growth Series
Part 1 | China’s AI Boom: From Compute Constraints to Commercial Momentum
Part 2 | China’s Next Phase in Healthcare Innovation
Part 3 | China Industrials: Growth Beneath Weak Headlines
